How can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?
Lea Bucher
Advertisement
Lea Bucher is Principal at Executive Insight.
Articles by Lea Bucher
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Brent Saunders: Eyeing New Horizons
2
TrumpRX Has a Blind Spot and It Can Redefine Patient Access
3
Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial
4
FDA Approves Amgen's Uplizna for Generalized Myasthenia Gravis With Positive AChR or MuSK Antibodies
5
